BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Nucletron Corporation, An Elekta Company, Installs Esteya For Treating Skin Cancer In Major U.S. Center


12/13/2013 10:05:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK
, Dec. 13, 2013 /PRNewswire/ -- The first Esteya® electronic brachytherapy system in the United States has been installed at New York's Memorial Sloan-Kettering Cancer Center. Esteya by Nucletron, an Elekta company, is a new approach for skin cancer treatment that relies on a small, high dose rate (HDR) X-ray source to apply high precision radiotherapy directly to the cancer site.

"With support from Elekta, Memorial Sloan-Kettering will lead a multicenter clinical study with the goal to further improve skin cancer treatment," says John Lapre, Executive Vice President, Elekta Brachytherapy. "With its leading role at the forefront of brachytherapy research, the hospital will help advance the quality of patient care and add to the evidence base that caregivers need for their clinical decisions."

Esteya features an efficient workflow, easy patient set-up, and a short, less than three-minute, treatment delivery. The system's compact design and reduced shielding requirements also make treatment with Esteya highly accessible, enabling clinicians to treat lesions virtually anywhere patients are seen in the clinic.

For more information about Esteya, visit www.esteya.com.

Availability of Esteya in identified markets is subject to regulatory approvals.

For further information, please contact:
Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email: johan.andersson@elekta.com
Time zone: CET: Central European Time

Michelle Joiner, Director, Global Public Relations and Brand Management, Elekta
Tel: +1 770-670-2447, email: michelle.joiner@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

SOURCE Elekta



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES